RT Journal Article
SR Electronic
T1 The ETKA study - Impact of early therapy termination on treated phonemes in conversational speech tasks in children aged 5 to 6 years with phonologically delayed development: protocol for a multicenter randomized controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.14.22273887
DO 10.1101/2022.04.14.22273887
A1 Detter-Biesl, Doris
A1 Schwartz, Bernhard
YR 2022
UL http://medrxiv.org/content/early/2022/04/18/2022.04.14.22273887.abstract
AB Background Children with speech and language disorders frequently display speech sound disorders, the treatment of which improves children’s ability to communicate. However, there is a significant gap between those therapy capacities needed and those provided in Austria. In addition, as the effect of early therapy termination has not yet been systematically evaluated, the aim of this project is to investigate the influence of an early therapy termination on phonological processes in children aged 5 to 6 years with phonologically delayed development.Methods/Design Forty 5- to 6-year-old children, currently participating in speech therapies in the Upper Austrian region will participate in this multicenter randomized controlled trial. The participants will be randomly allocated to either the intervention group (early therapy termination) or the control group (uninterrupted ongoing therapy) by envelop randomization. Phoneme accuracy in spontaneous speech determined during 15 minutes of conversational sampling and phoneme accuracy for single-word production determined with the PLAKKS assessment will be used to assess therapy efficacy. The results from both groups will be compared regarding the correct use of the target phoneme/consonant cluster in conversational speech situation.Discussion This study will explore the effect of early therapy termination on speech sound disorders in 5- to 6-yearold children. If an early termination exhibits non-inferiority to the current ongoing therapy, therapy resources could be used more effectively. Subsequently, earlier therapy starts for more children could be facilitated and negative consequences of delayed therapies could be counteracted.Ethics and dissemination The study was approved by an institutional review board (ID: A-2019-035). Dissemination will be achieved through peer-review conferences and journals.Trial registration The study is registered at ClinicalTrials.gov (Identifier: NCT03972891, Registered 4 June 2019, https://www.clinicaltrials.gov/ct2/show/NCT03972891).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03972891Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT03972891 Funding StatementThis study was fully supported by the University of Applied Sciences for Health Professions Upper Austria under [grant number P-2018-044, internal university fund, “ETKA”]. The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was provided by the compliance with the provisions of the Helsinki Declaration ethical standards for clinical research and is in line with the rules of good scientific practice for future research projects or academic work. The study protocol (v1.01 from 21.01.2019) was approved by universities? institutional review board ((?Ethik- und Forschungskomitee (EF) der FH Gesundheitsberufe OÖ) in February 2019 (A-2019-035) and was published on ClinicalTrials.gov in June 2019 (Identifier: NCT03972891). The ethics board will be informed about all substantial study protocol changes via amendments. The amendments will be signed by all the signatories to the original protocol. All participants, the legal guardians of the children and the therapists, will be informed about the study by the study members. In addition, children, and their legal guardians (i.e. mainly the parents) will receive additional information about the study procedure by the speech therapist. While the study participants (i.e. children receiving speech therapy) will be asked for a verbal informed consent, their legal guardians will be asked to sign a written informed consent for study participation. Children?s verbal informed consent will be documented in the case report form.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableNo datasets were generated or analysed during the current study. All relevant data from this study will be made available on ClinicalTrials.gov upon study completion. In accordance with the General Data Protection Regulation of the European Union, personal data will be adequately protected and will not be publicly disclosed.